Sale of BBI Group – A&O advising Exponent
16 June 2021
Allen & Overy is advising Exponent Private Equity (Exponent) on its agreement to sell BBI Group (BBI) to Novo Holdings, a global investor in life sciences companies.
BBI is a leading supplier of products and services to the global diagnostics and life sciences industries, providing critical reagents and immunoassay development, lateral flow development, diagnostic manufacturing services, and smartphone reader technologies.
The A&O team advising Exponent is led by private equity partner Gordon Milne with senior associate Jeremy Wilkins, associates Beth Tulley and Felix Jiang and trainee, Angela Chan. The wider team included leveraged finance partners Neil Sinha and Adam Zecharia with senior associate James Green and associate Chris Watkins; tax counsel Tim Harrop with associates Patrick Rohan and Sorsha Reilly; and antitrust partner Alasdair Balfour with senior associate David Weaver, associate Conor Slowey and trainee Alexander Westin-Hardy.
Earlier this month A&O also advised Exponent on its sale of BBI Healthcare to Venture Life Group plc. The deal follows a number of transactions on which A&O has advised Exponent since the beginning of 2021, including the acquisition of Gü, the acquisition of Proper and its merger with Eat Real, the acquisitions of Fudco and Everest Dairies, the demerger of Moonpig from the Photobox Group, and on the subsequent IPO of Moonpig.